Share chart Cardiol Therapeutics Inc.
Extended chart
Simple chart
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. more detailsMain settings
| IPO date | 2019-01-15 |
|---|---|
| ISIN | CA14161Y2006 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | cad |
| Сайт | link |
| Change price per day: | +7.76% (1.16) |
|---|---|
| Change price per week: | +17.92% (1.06) |
| Change price per month: | +15.74% (1.08) |
| Change price per 3 month: | +5.93% (1.18) |
| Change price per half year: | -20.89% (1.58) |
| Change price per year: | -51.36% (2.57) |
| Change price per 3 year: | -0.7937% (1.26) |
| Change price per 5 year: | -39.99% (2.083) |
| Change price per year to date: | -0.7937% (1.26) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 0 | 0 |
| P/BV | 6.06 | 1 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -106.99 | 0 |
| ROE, % | -138.47 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.0054 | 10 |
| Debt/Ratio | 0.005 | 10 |
| Debt/Equity | 0.2885 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 120.28 | 10 |
| Yield EPS, % | -2.74 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| MMCAP International, Inc. SPC | 2 953 300 | 4.33 |
| AdvisorShares Investments, LLC | 1 189 978 | 1.75 |
| Tejara Capital Ltd | 1 116 676 | 1.64 |
| AXS Investments, LLC | 697 651 | 1.02 |
| Lion Street Advisors, LLC | 192 700 | 0.28 |
| Bank of Montreal/Can/ | 104 479 | 0.15 |
| We Are One Seven, LLC | 100 000 | 0.15 |
| Laird Norton Trust Company, LLC | 100 000 | 0.15 |
| Cambridge Investment Research Advisors Inc. | 85 201 | 0.12 |
| Credit Suisse Ag/ | 80 000 | 0.12 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. David G. Elsley MBA | President, CEO & Director | 550.14k | |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director | 216.79k | |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer | 379.39k | |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development | 549.01k | 1962 (63 years) |
| Trevor Burns | Investor Relations | N/A | |
| Mr. John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
About company
Address: Canada, Oakville, 2265 Upper Middle Road East - Open in google maps, Open in yandex maps
Website: https://www.cardiolrx.com
Website: https://www.cardiolrx.com
